Dexmecamylamine
- Generic Name
- Dexmecamylamine
- Drug Type
- Small Molecule
- Chemical Formula
- C11H21N
- CAS Number
- 107538-05-6
- Unique Ingredient Identifier
- 5Y1141YI4U
- Background
Dexmecamylamine has been used in trials studying the basic science and treatment of Patients, Depression, Drug Abuse, Pharmacokinetics, and Renal Impairment, among others.
A Study to Assess Safety and Tolerability as Well as Absorption and Excretion of TC-5214 in Medically Stable Elderly Subjects
Phase 1
Completed
- Conditions
- Elderly Subjects 65 Years and Older, Healthy or With a Stable Disease and Treatment.
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT01239771
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder.
- First Posted Date
- 2010-09-09
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 696
- Registration Number
- NCT01197508
- Locations
- 🇺🇦
Research Site, Vinnytsya, Ukraine
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive DisorderDepression
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 295
- Registration Number
- NCT01180400
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
To Investigate Safety, Tolerability and Pharmacokinetics of TC-5214 in Healthy Male Japanese Subjects
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01175564
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)
Phase 3
Completed
- Conditions
- Major Depressive DisorderDepression
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 319
- Registration Number
- NCT01157078
- Locations
- 🇮🇳
Research Site, Mysore, India
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive DisorderDepression
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2409
- Registration Number
- NCT01153347
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- MDDDepressionMajor Depressive Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 813
- Registration Number
- NCT01152554
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
To Investigate the Safety and Tolerability of TC-5214 Following Oral Administration of Multiple Doses for up to 8 Days
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT01145768
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00899977
- Locations
- 🇺🇸
Piedmont Medical Research, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath